| 創建日期 | 上櫃日期 | 董事長 | 總經理 |
|---|---|---|---|
| 101/12/21 | 108/06/28 | 劉理成 | 劉理成 |
| EPS | 本益比 | 股價淨值比 | 現金殖利率 |
| -0.64(Q2) | 0 | 2.84 | 0% |
| 實收資本額 | 已發行普通股 | ||
| 3,048,384,540 | 304,838,454 | ||
| 主要經營業務 | |||
| 生物相似藥及新藥研發生技藥品委託開發暨生產服務(CDMO) | |||
| 公司網址 | |||
| eirgenix.com | |||
台康生技(6589) 月營收報表
| 年度/月份 | 營業收入（單位：千元） | 累計營業收入（單位：千元） | |||||
|---|---|---|---|---|---|---|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 | |
| 2023/08 | 63,085 | 95,779 | 1.1% | -34.1% | 480,137 | 927,050 | -48.2% |
| 2023/07 | 62,417 | 133,133 | 19.4% | -53.1% | 417,052 | 831,271 | -49.8% |
| 2023/06 | 52,281 | 108,521 | -0.5% | -51.8% | 354,635 | 698,138 | -49.2% |
| 2023/05 | 52,535 | 118,741 | 56.8% | -55.8% | 302,354 | 589,617 | -48.7% |
| 2023/04 | 33,497 | 109,331 | -48.7% | -69.4% | 249,819 | 470,876 | -46.9% |
| 2023/03 | 65,269 | 74,873 | -19.4% | -12.8% | 216,322 | 361,545 | -40.2% |
| 2023/02 | 80,999 | 64,746 | 15.6% | 25.1% | 151,053 | 286,672 | -47.3% |
| 2023/01 | 70,054 | 221,926 | -47.4% | -68.4% | 70,054 | 221,926 | -68.4% |
| 2022/12 | 133,101 | 193,085 | -15% | -31.1% | 1,481,016 | 1,697,359 | -12.7% |
| 2022/11 | 156,658 | 123,984 | 19.1% | 26.4% | 1,347,915 | 1,504,274 | -10.4% |
| 2022/10 | 131,552 | 106,476 | -0.8% | 23.5% | 1,191,257 | 1,380,290 | -13.7% |
| 2022/09 | 132,655 | 78,908 | 38.5% | 68.1% | 1,059,705 | 1,273,814 | -16.8% |
| 2022/08 | 95,779 | 173,837 | -28% | -44.9% | 927,050 | 1,194,906 | -22.4% |
| 2022/07 | 133,133 | 403,866 | 22.7% | -67% | 831,271 | 1,021,069 | -18.6% |
| 2022/06 | 108,521 | 113,578 | -8.6% | -4.4% | 698,138 | 617,203 | 13.1% |
| 2022/05 | 118,741 | 142,897 | 8.6% | -16.9% | 589,617 | 503,625 | 17.1% |
| 2022/04 | 109,331 | 115,940 | 46% | -5.7% | 470,876 | 360,728 | 30.5% |
| 2022/03 | 74,873 | 82,966 | 15.6% | -9.8% | 361,545 | 244,788 | 47.7% |
| 2022/02 | 64,746 | 71,363 | -70.8% | -9.3% | 286,672 | 161,822 | 77.2% |
| 2022/01 | 221,926 | 90,459 | 14.9% | 145.3% | 221,926 | 90,459 | 145.3% |
| 2021/12 | 193,085 | 73,015 | 55.7% | 164.4% | 1,697,359 | 1,070,911 | 58.5% |
| 2021/11 | 123,984 | 77,856 | 16.4% | 59.2% | 1,504,274 | 997,896 | 50.7% |
| 2021/10 | 106,476 | 86,044 | 34.9% | 23.7% | 1,380,290 | 920,040 | 50% |
| 2021/09 | 78,908 | 267,786 | -54.6% | -70.5% | 1,273,814 | 833,996 | 52.7% |
| 2021/08 | 173,837 | 54,220 | -57% | 220.6% | 1,194,906 | 566,210 | 111% |
| 2021/07 | 403,866 | 70,491 | 255.6% | 472.9% | 1,021,069 | 511,990 | 99.4% |
| 2021/06 | 113,578 | 64,331 | -20.5% | 76.6% | 617,203 | 441,499 | 39.8% |
| 2021/05 | 142,897 | 57,030 | 23.3% | 150.6% | 503,625 | 377,168 | 33.5% |
| 2021/04 | 115,940 | 89,357 | 39.7% | 29.7% | 360,728 | 320,138 | 12.7% |
| 2021/03 | 82,966 | 95,388 | 16.3% | -13% | 244,788 | 230,781 | 6.1% |
| 2021/02 | 71,363 | 86,818 | -21.1% | -17.8% | 161,822 | 135,393 | 19.5% |
| 2021/01 | 90,459 | 48,575 | 23.9% | 86.2% | 90,459 | 48,575 | 86.2% |
| 2020/12 | 73,015 | 84,755 | -6.2% | -13.9% | 1,070,911 | 477,016 | 124.5% |
| 2020/11 | 77,856 | 41,970 | -9.5% | 85.5% | 997,896 | 392,261 | 154.4% |
| 2020/10 | 86,044 | 29,952 | -67.9% | 187.3% | 920,040 | 350,291 | 162.6% |
| 2020/09 | 267,786 | 27,115 | 393.9% | 887.6% | 833,996 | 320,339 | 160.3% |
台康生技(6589) 歷年營收季增率
| 年度/季別 | 營收季增率 | 近4季營收季增率 | 年度/季別 | 營收季增率 | 近4季營收季增率 |
|---|---|---|---|---|---|
| 2023Q2 | -36.06% | -14.84% | 2020Q3 | 86.27% | 44.04% |
| 2023Q1 | -48.66% | -9.81% | 2020Q2 | -8.69% | 9.77% |
| 2022Q4 | 16.52% | -0.15% | 2020Q1 | 47.30% | 31.35% |
| 2022Q3 | 7.42% | -16.59% | 2019Q4 | 74.86% | 20.71% |
| 2022Q2 | -6.90% | -1.97% | 2019Q3 | -40.07% | 8.21% |
| 2022Q1 | -14.64% | 6.88% | 2019Q2 | 84.04% | 26.97% |
| 2021Q4 | -35.50% | 12.35% | 2019Q1 | 8.56% | 2.19% |
| 2021Q3 | 76.31% | 21.19% | 2018Q4 | 25.54% | -7.41% |
| 2021Q2 | 52.14% | 14.90% | 2018Q3 | -17.13% | -10.19% |
| 2021Q1 | 3.32% | 1.31% | 2018Q2 | -4.20% | 6.13% |
| 2020Q4 | -39.64% | 8.10% | 2018Q1 | -22.89% | 3.78% |
評論0